DaVita Upgraded to Outperform - Analyst Blog
January 25 2012 - 11:00AM
Zacks
We have upgraded our recommendation on DaVita
Inc. (DVA) to Outperform from Neutral based on the
company’s strong cash flows and strategic acquisitions. The bundled
ESRD payment system is also expected to be a long-term
positive.
DaVita reported third-quarter 2011 operating earnings of $138.2
million or $1.45 per share, exceeding the Zacks Consensus Estimate
by a penny. Results were also higher than the $119.5 million or
$1.15 per share earned in the comparable quarter of 2010.
DaVita has been generating strong operating cash flow accruing
from improved earnings and robust cash collections, leading to a
4-year CAGR (2007–2010) of 13.1%. Higher-than-expected cash flow
during the first three quarters of 2011 also allowed the company to
raise its 2011 operating cash flow guidance to $1.02–1.10 billion
from $900–980 million. The company projects similar growth in the
future and believes that it will be able to meet its capital
expenditures, as well as repurchase shares and spend on
acquisitions.
In addition to improving its operating performance, DaVita
constantly seeks to generate cost efficiencies. The recent
long-term Epogen purchase deal with Amgen
Inc. (AMGN) is expected to significantly reduce
the company’s expenditure on Epogen, a medicine used for increasing
red blood cells in kidney patients.
Moreover, DaVita is regularly expanding via acquisitions. In
January 2012, the company’s subsidiary – Paladina Health LLC –
announced the acquisition of ModernMed, which operates clinics and
physician practices in 12 states across the U.S.
However, DaVita is facing multiple investigations for
over-billing of Medicare and over-use of Epogen. If the charges are
found to be true, the company will not only suffer substantial
reduction in goodwill, but will also face several lawsuits and
might be heavily fined, weighing on the financials.
Moreover, a significant portion of DaVita’s dialysis and related
lab services revenues are generated from patients who have
commercial payors as the primary payor. However, unemployment may
result in the shifting of people from commercial insurance schemes
to more affordable government schemes.
Moreover, the shift will be harmful as the Medicaid was reduced
by many states in 2011 and many others are considering the
possibility of reducing the rate. Furthermore, almost 87% of
DaVita’s patients already use Medicare or Medicaid programs,
thereby leading to additional pressure on the company, as
inadequacy of government reimbursements will substantially affect
profitability.
The Zacks Consensus Estimate for DaVita’s fourth-quarter
earnings is currently $1.48 per share, up about 31% year over year.
None of the 12 firms covering the stock revised their estimates in
the last 30 days. For 2011, earnings are expected to be about $5.05
per share, climbing about 15% year over year.
DaVita currently caries a Zacks #1 Rank, implying a short-term
‘Strong Buy’ rating.
AMGEN INC (AMGN): Free Stock Analysis Report
DAVITA INC (DVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
DaVita (NYSE:DVA)
Historical Stock Chart
From May 2024 to Jun 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Jun 2023 to Jun 2024